tetano
Editor, Senior Moderator
J Virol Methods
. 2021 Dec 9;114408.
doi: 10.1016/j.jviromet.2021.114408. Online ahead of print.
A flow-through chromatography purification process for Vero cell-derived influenza virus (H7N9)
ChengRui Fei[SUP] 1 [/SUP], JingXia Gao[SUP] 1 [/SUP], ChengHua Fei[SUP] 2 [/SUP], Lei Ma[SUP] 1 [/SUP], WenYong Zhu[SUP] 1 [/SUP], LingYu He[SUP] 1 [/SUP], YaNan Wu[SUP] 1 [/SUP], ShaoHui Song[SUP] 1 [/SUP], WeiDong Li[SUP] 1 [/SUP], Jian Zhou[SUP] 3 [/SUP], GuoYang Liao[SUP] 4 [/SUP]
Affiliations
Abstract
Immunization is the most effective way to respond to an influenza epidemic. To produce Vero cell-derived influenza vaccines, a more efficient, stable and economical purification process is required. In this study, we purified the H7N9 influenza virus grown in Vero cells that were cultured in a serum-free medium by using a combination of anion exchange chromatography (AEC) and ligand-activated core chromatography (LCC), which avoids the virus capture step. After purification, 99.95% host cell DNA (hcDNA) (final concentration: 28.69 pg/dose) and 98.87% host cell protein (HCP) (final concentration: 28.28 ng/dose) were removed. The albumin content was 11.36 ng/dose. All these remnants met the current Chinese Pharmacopoeia and WHO requirements. The final virus recovery rate was 58.74%, with the concentration of hemagglutinin recorded at 132.12 μg/mL. The flow-through chromatography purification process represents an alternative to the existing processes for cell-derived influenza viruses and might be suitable for the purification of other viruses as well.
Keywords: H7N9 influenza virus; Vero cell; flow-through chromatography; purification process.
. 2021 Dec 9;114408.
doi: 10.1016/j.jviromet.2021.114408. Online ahead of print.
A flow-through chromatography purification process for Vero cell-derived influenza virus (H7N9)
ChengRui Fei[SUP] 1 [/SUP], JingXia Gao[SUP] 1 [/SUP], ChengHua Fei[SUP] 2 [/SUP], Lei Ma[SUP] 1 [/SUP], WenYong Zhu[SUP] 1 [/SUP], LingYu He[SUP] 1 [/SUP], YaNan Wu[SUP] 1 [/SUP], ShaoHui Song[SUP] 1 [/SUP], WeiDong Li[SUP] 1 [/SUP], Jian Zhou[SUP] 3 [/SUP], GuoYang Liao[SUP] 4 [/SUP]
Affiliations
- PMID: 34896455
- DOI: 10.1016/j.jviromet.2021.114408
Abstract
Immunization is the most effective way to respond to an influenza epidemic. To produce Vero cell-derived influenza vaccines, a more efficient, stable and economical purification process is required. In this study, we purified the H7N9 influenza virus grown in Vero cells that were cultured in a serum-free medium by using a combination of anion exchange chromatography (AEC) and ligand-activated core chromatography (LCC), which avoids the virus capture step. After purification, 99.95% host cell DNA (hcDNA) (final concentration: 28.69 pg/dose) and 98.87% host cell protein (HCP) (final concentration: 28.28 ng/dose) were removed. The albumin content was 11.36 ng/dose. All these remnants met the current Chinese Pharmacopoeia and WHO requirements. The final virus recovery rate was 58.74%, with the concentration of hemagglutinin recorded at 132.12 μg/mL. The flow-through chromatography purification process represents an alternative to the existing processes for cell-derived influenza viruses and might be suitable for the purification of other viruses as well.
Keywords: H7N9 influenza virus; Vero cell; flow-through chromatography; purification process.